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ttp://dx.doi.org/10.1016/j.jmoldx.2016.03.009High-resolution human leukocyte antigen (HLA) matching reduces graft-versus-host disease and im-
proves overall patient survival after hematopoietic stem cell transplant. Sanger sequencing has been the
gold standard for HLA typing since 1996. However, given the increasing number of new HLA alleles
identified and the complexity of the HLA genes, clinical HLA typing by Sanger sequencing requires
several rounds of additional testing to provide allele-level resolution. Although next-generation
sequencing (NGS) is routinely used in molecular genetics, few clinical HLA laboratories use the tech-
nology. The performance characteristics of NGS HLA typing using TruSight HLA were determined using
Sanger sequencing as the reference method. In total, 211 samples were analyzed with an overall accuracy
of 99.8% (2954/2961) and 46 samples were analyzed for precision with 100% (368/368) reproducibility.
Most discordant alleles were because of technical error rather than assay performance. More important,
the ambiguity rate was 3.5% (103/2961). Seventy-four percentage of the ambiguities were within the
DRB1 and DRB4 loci. HLA typing by NGS saves approximately $6000 per run when compared to Sanger
sequencing. Thus, TruSight HLA assay enables high-throughput HLA typing with an accuracy, precision,
ambiguity rate, and cost savings that should facilitate adoption of NGS technology in clinical HLA
laboratories. (J Mol Diagn 2016, 18: 668e675; http://dx.doi.org/10.1016/j.jmoldx.2016.03.009)Supported by institutional support from University of North Carolina
Hospitals (M.M., R.P., J.C.) and University of North Carolina School of
MedicineDepartment of Pathology andLaboratoryMedicine (E.T.W., J.L.S.).
Disclosures: E.T.W. reports nonfinancial support from Illumina, Inc., dur-
ing the conduct of the study. Illumina, Inc. generously provided the reagents
for conducting the study.It is widely accepted that human leukocyte antigen (HLA)
matching reduces patient morbidity and mortality after he-
matopoietic stem cell transplantation (HSCT).1 The current
standard of care is high-resolution HLA typing by Sanger
sequencing or sequence-based typing (SBT). High-resolution
HLA typing is defined as a set of alleles that specifies and
encodes the same protein sequence for the peptide-binding
region of an HLA molecule. However, SBT cannot accu-
rately phase heterozygous alleles and provides limited
sequencing information. Traditionally, HLA typing by SBT
typically involves sequencing only exons 2, 3, and 4 of HLA
class I genes and exons 2 and 3 of HLA class II genes. Since
the regulatory requirement was established for high-
resolution HLA typing for HLA-A/B/C/DRB1 in 2005,
many clinical laboratories are putting significant resources
toward ambiguity resolution.2 Even as several restrictions
were removed, such as the requirement to exclude rare al-
leles, there is still a growing list of ambiguities that requirestigative Pathology and the Association for Madditional testing and delay patient results. The issue of
ambiguities is a testament to the complexity of the HLA re-
gion in the human genome with >13,000 alleles identified to
date.3 The combination of the inability to phase heterozygous
alleles and the growing number of HLA alleles has led to a
significant number of ambiguities in HLA typing that require
time-consuming and costly additional tests to be performed.
In 2004, Adams et al4 reported the ambiguity rate for HLA-A,
HLA-B, and HLA-C of 24% to 41%. Three years later,
Voorter et al5 reported that ambiguities for HLA-A, HLA-B,
and HLA-C had increased to approximately 50%.olecular Pathology. Published by Elsevier Inc. All rights reserved.
NGS for Clinical HLA TypingCurrently, our experience is that ambiguity resolution is
required in 53% of patient specimens to determine a specific
allele (E.T. Weimer and J.L. Schmitz, unpublished obser-
vation). This high level of additional testing delays patient
HLA typing results and increases the cost of HLA typing.
With no sign that the number of HLA alleles identified will
decline and the increasing application of typing of addi-
tional loci (DPB1 and DRB3/4/5), there is a great need for a
technology that allows for accurate high-resolution HLA
typing without the requirement of additional testing.3,6e8
Next-generation sequencing (NGS) technology is the
massive parallel sequencing of clonal DNA molecules. By
using unique molecular signatures or barcodes, many sam-
ples can be pooled together and sequenced simultaneously.
A key feature of the NGS method is the ability to generate
massive amounts of genetic data from many DNA mole-
cules simultaneously.9,10 The combination of clonal DNA
sequencing and application of long-range PCR techniques to
increase HLA genomic information aids in the reduction in
HLA allele ambiguities. For example, Danzer et al11 used
long-range PCR of HLA genes and NGS to demonstrate an
average ambiguity reduction of 93.5% for HLA-A, HLA-B,
HLA-C, DRB1, DQB1, and DPB1. Although the ambiguity
reduction varied by locus [ie, the reduction of DRB1 was
less pronounced (46.1%)], this was still considered signifi-
cant given the amount of additional testing required by SBT.
HLA typing by NGS using long-range PCR techniques to
increase genomic coverage of HLA genes has proven effec-
tive at improving ambiguity resolution.11e14 The increased
genomic coverage is partly what enables the accurate phasing
of heterozygous bp positions often observed in SBT.13,15
Several recent reports have demonstrated the feasibility of
using NGS technology to provide >97% concordance with
SBT.11,13,15e17 Although the high-throughput nature of NGS
is thought to be cost-effective for HLA typing, this has yet to
be shown. More important, previous reports focused on
laboratory-developed assays rather than commercially
available reagents.11e14,17,18 With the increasing availability
of commercial NGS HLA reagents, there is a need to better
understand each assay’s characteristics and their utility to
solve the limitations of SBT.
In this study, we evaluated the performance of the TruSight
HLA assay, a commercially available NGS assay for HLA
typing, to not only accurately type HLA alleles but also identify
a set of quality control criteria required to ensure accurate HLA
allele determination. More important, we also performed a cost
analysis between NGS and SBT for HLA typing that provides
thefirst evidence thatNGS is a cost-effective alternative toSBT.
Materials and Methods
Patient Samples, DNA Extraction, and HLA Gene
Amplification
Two-hundred and eleven samples that were already high-
resolution HLA typed were used for comparison and clinicalThe Journal of Molecular Diagnostics - jmd.amjpathol.orgvalidation. An additional 79 samples of genomic DNA
extracted from buccal swabs from patients and donors under
evaluation for HSCT were also used. Genomic DNA was
extracted from each sample using Qiagen DNA Tissue
Extraction kits (Qiagen, Valencia, CA). The study was
approved by the Institutional Review Board of the Univer-
sity of North Carolina at Chapel Hill.
For HLA gene amplification, primers specific for each
HLA gene were used in a long-range PCR. DNA was
quantified using a QuBit fluorometer (Life Technologies,
Carlsbad, CA). After quantification, sample DNA was
diluted to 10 ng/mL. For buccal swabs, 40 of the 79 samples
received additional purification according to the manufac-
turer’s instructions. Fifty nanogram of genomic DNA was
used for each HLA locus and amplified according to the
manufacturer’s instructions. PCR amplicons were visualized
using 2% agarose gel electrophoresis before preparing NGS
libraries. Twenty-four samples (192 HLA loci) were run in a
single NGS experiment. A sample with a known HLA
typing was run on each NGS run to ensure library prepa-
ration, data quality, and analysis were of sufficient quality to
ensure accurate HLA typing.
TruSight HLA Library Preparations and NGS Sequencing
Amplified DNA for NGS sequencing was prepared according
to the supplied instructions (Illumina, Inc., San Diego, CA).
Briefly, amplified DNA was purified using magnetic
AMPure XP beads, fragmented, and Illumina-specific adap-
tors were applied using a tagmentation enzyme supplied by
Illumina. After tagmentation, fragments were purified using
AMPure XP beads and patient-specific indices were added to
individual HLA loci by a short PCR, followed by magnetic
bead purification. Post-barcoding samples were pooled
and the libraries quantified using QuBit fluorimeter. The size
of HLA libraries was determined using TapeStation
Bioanalyzer 2200.
To assess sequencer-based errors, a 1% to 5% concen-
tration of 12.5 pmol/L PhiX control (Illumina, San Diego,
CA) was spiked into pooled HLA libraries. Pooled HLA
libraries and PhiX control were loaded onto the cartridge
and 2  250 bp sequencing was performed using a regular
flow cell on an Illumina MiSeq. Demultiplexing and gen-
eration of FASTQ files was performed on the MiSeq
system. A total of 34 MiSeq runs were performed and used
for quantification of sequencing metrics.
Sample Analysis
Sample analysis was performed using Conexio Assign for
TruSight HLA software version 1.0.0.729 supplied by
Illumina. Sample consensus sequences were compared to
the IMGT/HLA database (version 3.15 to 3.20). A complete
HLA genotype was determined by loading FASTQ files into
Conexio Assign software. Samples were analyzed for mis-
matches throughout the entire amplified region of the HLA669
Table 1 Amplification Size for HLA Genes Using TruSight HLA
Loci
Sequencer
region (kb)
A 4.1
B 2.6
C 4.2
DPA1 10.3
DPB1 9.7
DQA1 7.3
DQB1 7.1
DRB1/3/4/5 4.1
HLA, human leucocyte antigen.
Weimer et algenes. Mismatches that represented potential novel HLA
alleles were noted. Ambiguity resolution was performed by
Sanger sequencing with analysis on uTYPE 6.0 (SeCore
HLA kit; Life Technologies).
Cost Analysis
The cost analysis between SBT and NGS was performed
using the available list price for each reagent necessary for
the respective technologies. For NGS, reagents included
HLA locusespecific primers, library preparation, and
sequencing reagents. For Sanger sequencing, reagents
included HLA locusespecific primers, ExoSAP, sequencing
reagents (cathode, anode, polymer), sequence-specific oli-
gonucleotides, and group-specific sequencing primers for
ambiguity resolution. Ambiguity resolution was added to
each technology using laboratory-specific 53% for Sanger
sequencing and 3% for NGS. Instrumentation cost was
excluded for the analysis. An estimation of time required for
each method was determined by averaging the hands-on
time from amplification to completed analysis (including
ambiguity resolution) for each technologist (n Z 5) per-
forming the assay. The average labor time was multiplied by
the average hourly rate for HLA technologists at UNC
Hospitals. Assay time was defined as the time from PCR to
completion of sequencing analysis. Turnaround-time (TAT)
was determined for all HSCT-related HLA typings from
receiving in laboratory to verification of results in calendar
days. Date range for NGS (n Z 323) was August to
December 2015 and the same time period 1 year prior for
Sanger sequencing (n Z 324). NGS runs were between 10
and 23 patients per run, with HLA-A, HLA-B, HLA-C, HLA-
DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1
typed. Only HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-
DQB1, HLA-DPB1 were reported clinically. HLA-DQA1
and HLA-DPA1 typing were used for academic purposes.
For comparison, a maximum of five patients were run using
Sanger sequencing.
Statistical Analysis
Significant differences between two proportions were
determined by two-tailed probability test from the calculated
z-ratio. Significant differences between NGS and Sanger for
TAT were calculated using unpaired t-test with Welch’s
correction. P  0.05 was considered significant.
Results
HLA Gene Amplification Rates
To enrich HLA genes, genomic DNA was amplified by
long-range PCR. A known HLA-typed sample and negative
control were used with every PCR to ensure proper HLA
amplification and to assess for potential contamination.
There were no cases of PCR-based contamination670throughout the validation. The PCR fragment length for
each HLA gene is shown in Table 1, and a representative gel
electrophoresis of HLA amplicons is shown in Figure 1A.
Overall, the amplification success rate of HLA genes was
95.0% (2399/2526) (Figure 1B). Only 37 HLA class I genes
failed to amplify of 945 amplifications (3.9%) and 31 of the
37 were from buccal swabs. There were a total of 127 in-
cidences of no detectable PCR band on electrophoresis that
were subsequently sequenced and HLA typed (Figure 1, C
and D). DPA1 and DPB1 were the most difficult HLA genes
to amplify, most likely because of their length (Figure 1,
BeD). In addition, DPA1 and DPB1 had the lowest HLA
typing success overall. Amplification success was signifi-
cantly lower for DPA1 (P < 0.001), DPB1 (PZ 0.001), and
DQB1 (P Z 0.006) when using DNA isolated from buccal
swabs (BSs) compared to DNA from peripheral blood19
(Figure 1B). To determine the reason for decreased HLA
amplification rate from BSs, the effect of concentration and
quality of DNA on HLA typing was evaluated. Additional
purification of BSs significantly increased HLA typing rates
for DQB1 (PZ 0.048) and DPB1 (PZ 0.002) compared to
nonpurified samples (Figure 1E). Similarly, BSs with higher
concentrations were significantly more often successfully
HLA typed for DPA1 (P < 0.001) and DPB1 (P Z 0.001)
compared to lower concentrations (Figure 1F).Characteristics of HLA Library Fragments and NGS Data
NGS library fragments vary in size and DNA fragments
>1000 bp are less efficient at cluster generation on the
MiSeq than smaller fragments.19 To determine the DNA
fragment size generated using TruSight HLA, three (576
loci) pooled HLA libraries were analyzed using a TapeS-
tation Bioanalyzer. The average library fragment size was
1268 bp (95% CI, 856e1680 bp) (Figure 2A). Larger
fragment sizes aid in correct phasing of HLA alleles.15 Next,
overall read quality and depth of coverage were determined
for each HLA locus. The average percentage of
reads  Q30 was 96.1% (95% CI, 95.4%e96.7%) for all
HLA loci (Figure 2B). The lowest quality reads were
consistently observed with HLA-B and HLA-DQB1. The
average depth of coverage was 280 (95% CI, 270e289) forjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 1 HLA typing rates for peripheral blood and buccal swabs. A: Representative gel electrophoresis of TruSight HLA amplicons. B: Comparison between
peripheral blood (PB) and buccal swab (BS) HLA successful typing rates. C: Peripheral blood. D: Buccal swabs. C and D: Absence of a visible electrophoresis
band does not prevent accurate HLA typing. Gel electrophoresis bands were counted and compared to the overall ability of each sample to accurately HLA type.
E: Additional purification of buccal swabs provides better HLA typing. HLA typing was compared between buccal swab samples that were either used as extract
(nonpurified) or received additional magnetic bead-based purification (purified). F: Higher concentration buccal swabs outperform low concentration samples.
*P < 0.05, **P < 0.005.
NGS for Clinical HLA Typingall HLA loci (Figure 2C). These results indicate that NGS
data generated by TruSight HLA are high quality and core
exons within each HLA are covered beyond 250.
NGS Data Quality Metrics
To determine the quality of each library preparation and
sequencing run, cluster density, percentage of clusters
passing filter, percentage of reads  Q30, and error rate
were monitored using Illumina’s sequencing analysisA B
Figure 2 Characteristics of next-generation sequencing (NGS) library fragme
fragment size was determined from pooled libraries using a TapeStation Bioanalyze
Depth of coverages for each HLA loci. Light gray area indicates acceptable range
Dark gray area indicates acceptable range for HLA-DRB1/3/4/5. B and C: The nu
expressed as means  SD (AeC). n Z 3 (A).
The Journal of Molecular Diagnostics - jmd.amjpathol.orgviewer. The acceptable range for each parameter was
determined to be the average plus or minus 2 SDs or using
the MiSeq performance specifications provided by the
manufacturer. There were two runs in which PhiX was not
added to the pooled libraries before sequencing and thus no
error rate could be determined. The shaded areas in Figure 3
show the acceptable range for each parameter. For a run to
be considered high quality, it must fall within specific
ranges for each category. There were two runs that required
repeat sequencing because of reagent issues (Figure 3, BC
nts. A: NGS library fragment sizes generated using TruSight HLA. Library
r. B: Percentage of reads Q30. Shaded area indicates acceptable range. C:
for HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQB1, and HLA-DQA1.
mber of individual measurements is indicated within each column. Data are
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Figure 3 Characterization of next-generation
sequencing (NGS) data metrics. For 34 NGS runs,
cluster density, frequency of clusters passing filter,
percentage of reads  Q30, and error rate were
determined. All of the parameters were determined
using Sequence Analysis Viewer (SAV) after each
run. Error was determined by spiking in 1% to 5%
PhiX into pooled HLA libraries before sequencing.
Gray regions indicate acceptable range for each
parameter. AeC: Line indicates mean value. A:
Cluster density. B: Clusters passing filter. C: Fre-
quency of reads at or above Q30. D: PhiX error rate.
Two separate sequencing runs fell outside
acceptable range because of reagent issues.
Weimer et aland D). The average cluster density and proportion of
clusters passing filter were 1071  35 K/mm2 and
88%  1%, respectively (Figure 3, A and B). The average
percentage of read  Q30 was 80%  1% (Figure 3C). The
average error rate was 1.65%  0.1% (Figure 3D). After run
7, there was a 54.5% reduction in error rate variability
compared to the first six runs (Figure 3D). Establishing
these criteria is crucial for ensuring library preparation
consistency and sequencing performance over time.Table 2 Accuracy and Ambiguities for TruSight HLA Assay
Gene N
Allele level
mismatch % correct Ambiguities
Ambiguity
rate (%)
HLA-A 353 1 99.7 1* 0.3
HLA-B 353 1 99.7 0 0.0
HLA-C 353 0 100.0 0 0.0
HLA-DPA1 345 1 99.7 0 0.0
HLA-DPB1 354 0 100.0 0 0.0
HLA-DQA1 346 1 99.7 0 0.0
HLA-DQB1 345 0 100.0 0 0.0
HLA-DRB1 346 1 99.7 91y 26.3
HLA-DRB3 100 0 100.0 0 0.0
HLA-DRB4 23 0 100.0 11z 47.8
HLA-DRB5 43 1 97.7 0 0.0
Total 2961 6 99.8 103 3.5
*Ambiguity exists between 03:01:01, 11:01:01 pair, and 03:63/11:12.
yAmbiguities exist for the following HLA alleles: 03:01; 03:50, 08:04;
08:59, 15:01; 15:110, 13:01; 13:112, 16:02; 16:22, 14:54; 14:113; 14:125;
14:157, 15:02; 15:19, 13:02; 13:128.
zAmbiguities because of inability to accurately identify 01:03N.HLA Typing Comparison between Sanger and NGS
Clinical validation of HLA typing by NGS involves deter-
mination of the assay’s accuracy and precision compared to
the gold standard, Sanger sequencing. To determine TruSight
HLA assay accuracy, 211 samples for which existing
genomic DNA and high-resolution HLA typing was known
for each locus were used. Fifty of the 211 samples were
blinded (all authors were blinded). Forty-six samples were
used to assess assay reproducibility. HLA alleles were
considered equivalent on the basis of the National Marrow
Donor Program HLA reporting criteria. The National
Marrow Donor Program requires identification of eight null
(nonexpressed) HLA alleles within specific HLAG groups.20
All eight null HLA alleles could be identified or ruled out as
potential HLA alleles using TruSight HLA. Overall, accu-
racy for the assay was (2954/2961) 99.8% with a precision of
100% (Table 2). Two-hundred and sixty-five unique HLA
alleles were accurately identified by TruSight HLA672(Supplemental Table S1). Only ambiguities outside of HLA
G groups are considered significant because those alter the
peptide-binding region of the HLA protein. There were 103
(3.5%) ambiguities of 2961 alleles identified. Of 103 ambi-
guities, 91 (88.4%) were from DRB1 (26.3% of all DRB1
typings) and 11 (10.7%) were from DRB4 (47.8% of all
DRB4 typings) loci (Table 2). Because DRB4 is not
commonly part of HLA matching for HSCT, the impact on
routine clinical use is minimal. There was one ambiguity injmd.amjpathol.org - The Journal of Molecular Diagnostics
NGS for Clinical HLA Typingthe A locus (0.3%). All remaining HLA loci had no ambi-
guities. HLA typing by TruSight HLA demonstrated a 93.4%
reduction in ambiguities compared to Sanger sequencing.
The seven cases of incorrect HLA typing emphasized the
need for HLA-specific data criteria. Three of the seven in-
stances were because of allele dropout. Given those results,
HLA-specific data quality criteria were established. A depth
of coverage (DOC) of at least 100 and at least 81% of the
reads  Q30 were determined to be necessary for HLA-A,
HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1,
HLA-DPB1, HLA-DPA1 typing. Higher quality data (88%
of the reads are  Q30) was necessary for HLA-DRB3/4/5 to
prevent false identification of those alleles (Figure 2, B and
C). The sequencing and HLA-specific data quality metrics
were validated using the 50 blinded samples. Although the
above criteria are crucial for increased accuracy in HLA
typing results, samples could be accurately typed below
those thresholds. Samples were accurately typed with as few
as 67 reads and a 74% frequency of  Q30 reads (data not
shown). Higher DOC was a better HLA typing quality
predictor compared to quality scores (Table 3). Of note, if a
sample meets the sequencing run parameters but fails HLA-
specific criteria, HLA typing for that sample is not reported
and must be repeated. More important, repeat amplification
and NGS library preparation accurately typed all incorrect
samples, suggesting the incorrect HLA typing was because
of a technical error issue rather than an assay issue
(Table 3).
HLA Typing Cost Comparison between Sanger
Sequencing and NGS
As mentioned above, 53% of the HLA typings by Sanger
sequencing require additional tests to resolve ambiguities inTable 3 Quality Metrics on Incorrectly Typed Samples
ID*
Average %
of read  Q30 Average DOC HLA typing
84 93 30 DRB3 present
Repeaty No DRB3 present
141 91 77 DRB1*15:01
Repeaty 97 293 DRB1*12:01G
UNC9 DQB1*06 dropout
Repeaty 96 277 DQB1*06:02
122 94 49 DRB3 present
Repeaty No DRB3 present
2417 DQB1*06 dropout
Repeaty 95 277 DQB1*06:02
4609 DQB1*06 dropout
Repeaty 96 284 DQB1*06:03
UNC7 DRB1*04 dropout
Repeaty 89 164 DRB1*04:04
*All incorrect samples were flagged by the Conexio Assign for TruSight
HLA software.
yAll repeat testing was consistent with Sanger sequencing results.
DOC, depth of coverage; HLA, human leucocyte antigen.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgour laboratory. Ambiguity resolution delays patient results
and increases patient cost for HSCT. Given that there was
significant reduction in the number of ambiguities encoun-
tered by TruSight HLA, we hypothesized that NGS
sequencing would be more cost effective than typing by
Sanger sequencing. The relative cost of HLA typing by
Sanger sequencing and TruSight HLA was determined and
compared. For each technology, all reagent costs and rela-
tive hands-on time were considered. The average time for an
assay and hourly rate of the technologists were used to
calculate labor costs. TruSight HLA reagent costs were
41.8% ($270/patient) lower compared to Sanger sequencing
for HLA typing at all loci (Figure 4A). There was a 25%
($5/patient) reduction in labor (library preparation and
analysis) required for TruSight HLA compared to Sanger
sequencing. High-resolution HLA typing data for HLA-A/
HLA-B/HLA-C/HLA-DRB1/HLA-DQB1 costs between
NGS and Sanger were determined. The total cost to type
those HLA loci by NGS is approximately $250 ($50/HLA
locus) per patient and $380 ($76/HLA locus) per patient for
Sanger sequencing (Figure 4B). Thus, the more patients run
together for NGS the more cost savings that are realized. To
examine the impact of batching samples TAT for HLA
typing by NGS was compared to Sanger sequencing during
the same time period. The average TAT using NGS was
significantly faster (19 days, P < 0.001) compared to Sanger
sequencing (22 days) (Figure 4C). Thus, in addition to being
highly accurate, TruSight HLA is cost-effective while not
delaying patient HLA typing.Discussion
The analysis presented herein is not only the first charac-
terization and validation of the TruSight HLA assay for
HLA typing by NGS, but is also the first report of specific
sequencing and HLA criteria necessary for clinical reporting
of HLA results. TruSight HLA demonstrated efficient gen-
eration of long-range HLA amplicons (Figure 1) and NGS
libraries that consistently generated high-quality data
(Figures 2 and 3). The degree of concordance is consistent
with previous reports comparing different sequencing plat-
forms and NGS HLA assays17,21,22 (Table 2). The cost-
effectiveness of HLA typing by NGS is consistent with a
report by Stoddard et al23 on the use of NGS compared to
Sanger for diseases with multiple candidate genes
(Figure 4). Overall, TruSight HLA is a robust assay that
consistently provides accurate high-resolution HLA typing
with a dramatically reduced ambiguity rate, cost, and TAT.
Clinical implementation of new HLA typing technology
requires strict validation to provide HLA typing for pa-
tients. There are few clinical HLA laboratories performing
HLA typing by NGS compared to Sanger sequencing.
Establishing criteria for what should be considered suffi-
cient validation is a vital part of the process for clinical
laboratories. Several of the NGS runs experienced reagent673
A B C
, n
Figure 4 HLA typing cost comparison: next-generation sequencing (NGS) and Sanger sequencing. A: Cost analysis between NGS and Sanger sequencing was
performed using list prices for reagents and the mean labor time for amplification, library preparation, and analysis. The cost is based on NGS runs of 23
patients per run for all HLA loci. Ambiguity rate for Sanger sequencing (53%) and NGS (3.5%) were factored into final reagent and labor costs. B: Cost for
typing HLA-A/HLA-B/HLA-C/HLA-DRB1/HLA-DQB1 for various numbers of patients between NGS (black bars) and Sanger sequencing (white bars). C: Turn-
around-time (TAT) between Sanger (2014) sequencing and NGS (2015) for August to December. n Z 5 (A); n Z 323 (C, 2015); n Z 324 (C, 2014).
***P < 0.001.
Weimer et alissues that highlighted the need to establish guidelines for
an acceptable sequencing run to proceed to HLA analysis
(Figure 3, C and D). This report demonstrates one such
manner of approaching the issue. Without the criteria
presented herein, the accuracy of HLA typing would have
been significantly decreased. In addition, clinical labora-
tories must have a quality assurance system in place to
monitor assay performance. More important, DOC was a
better indicator for data quality than quality score
(Table 3). Higher quality scores were associated with less
phasing issues for the HLA region and thus incorporated
for quality assurance measures (data not shown). Tracking
the sequencing metrics meets this clinical laboratory
standard (Figure 3). As an additional level of quality
control, HLA-specific data quality criteria were deter-
mined (Figure 2). Application of these criteria allowed for
increased accuracy of HLA typing and reduced the po-
tential for false-positive HLA typings. In our experience,
failed HLA typing is most often because of poor sample
quality (Figure 1) or improper handling of the magnetic
beads (M. Montgomery and E.T. Weimer, unpublished
observation). Laboratories considering NGS for HLA
typing should examine their workload and the TAT
wanted. Thus far, NGS has improved the TAT for high-
resolution HLA typing, this will be dependent on the
frequency of samples the laboratory receives and the TAT
wanted. The cost benefit of NGS is greatly diminished as
the batching of samples is reduced (Figure 4C).
A thorough validation should not only determine whether
an assay performs robustly, but also identify areas of concern.
Consistent with previous reports, HLA typing ofDRB1/3/4/5
was the most difficult22,24,25 (Table 2). These issues arise674because of primer locations inhibiting the ability to resolve
certain HLA alleles. All instances where the software inap-
propriately identified DRB3/4/5 alleles had DOC of <80.
After application, the proposed HLA-specific criteria
(Figure 2, B and C), those samples would have been repeated
before reporting results. A known issue with PCR amplifi-
cation methods is the potential for allelic drop out. DQB1*06
(5% of DQB1*06 typings), DRB1*04 (2.9% of total
DRB1*04 typings), and B*27:05:02 (low amplification rate)
were found to be most susceptible to allelic drop out. This
occurred most often from low DNA concentration buccal
swabs and additional purification of buccal swabs before PCR
significantly reduced allele drop out (M. Montgomery and
E.T. Weimer, unpublished observations). Although several
reports have demonstrated that cluster generation and MiSeq
sequencing are less efficient with long DNA fragment
sizes,19,26 we and others have clearly demonstrated that DNA
fragments >1000 bp can effectively and reproducibly
generate high-quality NGS data using MiSeq (Figures 2
and 3).15 More work is needed to improve HLA typing of
DQB1, DRB1, and DRB4 to further reduce ambiguities and
cost. In addition, more time is needed to examine the impact
transitioning to HLA typing by NGSwill have on patient care
and the utility of whole gene sequencing.Acknowledgments
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